SPRINT Treatment Among Adults With Chronic Kidney Disease From 2 Large Health Care Systems
JAMA Network Open · 2025
DOI: 10.1001/jamanetworkopen.2024.53458 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2025. Verfasst von Manjula Kurella Tamura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
Importance It is unclear whether the effects of intensive vs standard blood pressure (BP) targets seen in clinical trials generalize to patients with chronic kidney disease (CKD) encountered in everyday practice due to differences in the distribution of cardiovascular risk factors and coexisting conditions.
Objective
To evaluate whether the beneficial and adverse effects of intensive vs standard BP control observed in the Systolic Blood Pressure Intervention Trial (SPRINT) are transportable to a target population of adults with CKD in clinical practice. Design, Setting, and Participants This comparative effectiveness study identified 2 populations with CKD who met the eligibility criteria for SPRINT between January 1 and December 31, 2019, in the Veterans Health Administration (VHA) and Kaiser Permanente of Southern California (KPSC). Baseline covariate, treatment, and outcome data from SPRINT were combined with covariate data from these populations to estimate the treatment effects in the target population, applying models that estimated outcomes using distributions in the trial. Analysis was performed between May 2023 and October 2024. Main Outcomes and Measures The main outcomes were major cardiovascular events, all-cause death, cognitive impairment, CKD progression, and adverse events at 4 years.
Results
A total of 85 938 patients (mean [SD] age, 75.7 [10.0] years; 81 628 [95.0%] male) from the VHA and 13 983 patients (mean [SD] age, 77.4 [9.6] years; 5371 [38.4%] male) from KPSC were included. Compared with 9361 SPRINT participants (mean [SD] age, 67.9 [9.4] years; 6029 [64.4%] male), these patients were older, had less prevalent cardiovascular disease, higher albuminuria, and used more statins. The associations of intensive vs standard BP control with major cardiovascular events, all-cause death, and adverse events were transportable from the trial to the VHA and KPSC populations; however, the trial’s effects on cognitive and CKD outcomes were not transportable in 1 or both clinical populations. Intensive vs standard BP treatment was associated with lower absolute risks for major cardiovascular events at 4 years by 5.1% (95% CI, −9.8% to 3.2%) in the VHA population and 3.0% (95% CI, −6.3% to 0.3%) in the KPSC population and higher risks for adverse events by 1.3% (95% CI, −5.5% to 7.7%) in the VHA population and 3.1% (95% CI, −1.5% to 8.3%) in the KPSC population. Conclusions and Relevance In this comparative effectiveness study, the reduction in fatal and nonfatal cardiovascular end points and the increase in adverse events observed in SPRINT were largely transportable to trial-eligible CKD populations from clinical practice, suggesting benefits of implementing intensive BP targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
- Geriatric Research, Education and Clinical Center, VA Palo Alto, Palo Alto, California.
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena.
- Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.
- Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
- Department of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, California.
Förderung
- NIDDK NIH HHS
- NIH HHS
Zitieren
APA
Kurella Tamura, M., Huang, M., An, J., Zhou, M., Niu, F., Sim, J. J., Pajewski, N. M., Gaussoin, S. A., Li, J., Odden, M. C., Chang, T. I., Charu, V., & Montez-Rath, M. E. (2025). SPRINT Treatment Among Adults With Chronic Kidney Disease From 2 Large Health Care Systems. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.53458
Vancouver
Kurella Tamura M, Huang M, An J, Zhou M, Niu F, Sim JJ, et al. SPRINT Treatment Among Adults With Chronic Kidney Disease From 2 Large Health Care Systems. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2024.53458
BibTeX
@article{KurellaTamura2025,
author = {Kurella Tamura, Manjula and Huang, Mengjiao and An, Jaejin and Zhou, Mengnan and Niu, Fang and Sim, John J and Pajewski, Nicholas M and Gaussoin, Sarah A and Li, June and Odden, Michelle C and Chang, Tara I and Charu, Vivek and Montez-Rath, Maria E},
title = {SPRINT Treatment Among Adults With Chronic Kidney Disease From 2 Large Health Care Systems},
journal = {JAMA Network Open},
year = {2025},
doi = {10.1001/jamanetworkopen.2024.53458}
}
EUVIMED